Member Info for B2HS2L

'but I continue to be right...'

guarantee's you are disliked, because it's untrue.

Dislike is emphasised by 'spiteful poisonous dross', responses, which not only do you deserve, but you already know they are coming your way.

So you post 'I continue to be right', like a calling card, and expect dross responses.

I know who's at fault, and your Narcism makes sure this happens every time.

No normal posters use I continue to be right.

You need to see a specialist.

The day the first 6103 patient is dosed is the day the platform hosts two programs - and preCISION becomes worth much more.

It will have become a true platform, (with 6207 dialled in for good measure).

GLALTH

According to CC @ TD Cowan conference, they haven't cut the data yet, so can't supply the mean PFS.

'But I continue to be right and you continue to be the abusive class'

I've ordered that for your headstone, prefixed with Here lies a TWAT.

Only Spike Milligan can approach that with 'I told you I was ill!'

To reinforce the message to posters like wyndrum that progress at Avacta is real.

Avacta announce the start of 4 trials with associated costs of those trials.

Financial suicide without a plan.

No way would such valuable IP become available so cheaply, unless a trial funding plan existed.

Such a plan has already begun, else management would be stalling awaiting a trigger from A N Other party.

B2HS2L

Posted in: AVCT

Posts: 6,108

RE: AVA6103 First person dosed competition 6 Mar 2026 15:33

Https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/LwUt6pCTp7n3eomJgfvTSA slide 14

Using digital vernier measurement off of my screen - 21.5mm = 13 weeks (Q1)

Centre of square blob is - 17.5mm from start of Q1 = 10.6 weeks

Therefore RNS scheduled for Wednesday 18.03.2026, + & - 1 day 😛😜🥵 - tongue in cheek

++++

I got the right week, so it seems the published charts are quite accurate.

It's got nothing to do with the digital vernier measurement, accuracy - or my screen!

GLALTH ❗❣️❗

Icecool has a set of figures he's keen on regarding what the company is worth.

But at the end of the day, Avacta will be sold for what's negotiated.

If everyone under the sun is expecting a megadeal, the chance that anyone's figures are quite close are not high.

I'm the right side of break even, and proceed assuming I have invested in a multibagger.

I'm happy to wait for a day - possibly this year, where my finances increase markedly.

GLALTH

Bad luck for those who aren't invested sufficiently when the balloon goes up.

The latest attempt at MAKEITUPASIGOALONG no better than previous attempts.

Please practice off this board. 🙄

..rather have an MOU..

RNS 07.03.2025 - Avacta announces data update for AVA6000

....Alan Ho, MD PhD, Chief of the Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center and member, Avacta Scientific Advisory Board, commented:

"We are very excited to move the development of AVA6000 to the next level to generate data that demonstrates clinically meaningful efficacy and durability of response in patients with previously treated salivary gland cancers.

....Christina Coughlin, CEO of Avacta Therapeutics commented:

"We are very pleased to advance to the expansion cohorts in the AVA6000 trial in these three indications with high unmet need. Our development of AVA6000 is proceeding according to plans and today's new data demonstrate the durability of the responses we have observed in the SGC indication.

+++

I'm expecting similar non committal words after trial launch.

I expect nothing at all if trial patients are experiencing difficulties.

Sorry to say we're going to need version two of * https://clinicaltrials.gov/study/NCT07454642?term=avacta&rank=2&tab=history *

available before dosing, let alone results. I polling this link often for an update.

Who is hosting the clinical development in patients with four solid tumors, their expertise, and locations.

Pancreatic cancer

Cervical cancer

Gastric cancer

Small cell lung cancer

It would be nice to think patient enrolment will be brisk.

Wishing them good fortune for the 2 and 3 week study results,

Everyone bar wyndrum and Toukankahmoon

I've been out of the house all day.

I now read many wyn posts strewn with narcistic C.R.A.P. and am appalled that this self indulgent prig is making himself at home on this BB once more.

The last few weeks have been much more focused and meaningful without wyn, even though Touk still persists.

Ignore or Filter for a FUD-Free-Future, you know it makes sense.

Don't engage - else we'll be hearing for ever more, how good Avacta has been for those exceptional trading abilities.

I thought we couldn't care less what this makeitupasIgoalong tosspot residing in neverland.

Aldebaran

* 'Ignore the fact that because its kinder it should sell for a premium over straight dox'

Using ava6k

Dr William Tap has declared that ‘if we can come up with a better treatment, then overnight it could become the standard of care.

Alleviating cancer patients of the side effects of doxorubicin is not optional for patients.

If they could, they will opt every time for avoiding the effects of the 'Red Devil'.

I see AVA6K becoming standard of care, the only caveat being the price of the 'old drug delivered in a new way'.

wrt magic crayons, the only magic is the pink ones are strawberry flavour. Unfortunately you can't see the lines made by the Vanilla one

BV - 13.12.2023 Investormeet Q/A:

FWIW (AVA6000) Question 36:

What happens to the free doxorubicin after it has been cleaved at the tumour site?

Will any post-cleavage dox circulate and cause possible toxicities? Also, what happens to the pre|CISION residue?

The pharmacokinetic data indicate that most of the doxorubicin released at the tumour site will enter cells but a small proportion gets into the circulation which is why the toxicities that we see, which are significantly reduced compared with standard doxorubicin administration, have a dose response.

The pre|CISION leaving group is measured in the urine.

Some Secondary Outcome Measures mention AVA10344.

Nothing in notes & AI draws a blank.

Everything I learned I learned from you Touk.

Here's hoping you aren't the one who is not fully invested when the sp step change occurs.

Please let us know how your wife responded if that happens, - there's always one.

Https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/LwUt6pCTp7n3eomJgfvTSA slide 14

Using digital vernier measurement off of my screen - 21.5mm = 13 weeks (Q1)

Centre of square blob is - 17.5mm from start of Q1 = 10.6 weeks

Therefore RNS scheduled for Wednesday 18.03.2026, + & - 1 day 😛😜🥵 - tongue in cheek

My Chinese model is predicting April 1st.

'somebody' overwound it though.

AVA6000 1a data cutoff = Sept 2025,

1b data cutoff = Oct 2025.

I'm expecting 6000 clinical trial data to be published, just not @ an investment opportunity in Boston,

and not necessarily close to news of AVA6103 start soon.